

ENDO PHARMACEUTICALS HOLDINGS INC  
Form 8-K  
March 31, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): March 31, 2008 (March 28, 2008)**

**Endo Pharmaceuticals Holdings Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**100 Endo Boulevard, Chadds Ford, PA**  
(Address of principal executive offices)

**001-15989**  
(Commission File Number)

**13-4022871**  
(I.R.S. Company

Identification No.)

**19317**  
(Zip Code)

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

**Registrant's telephone number, including area code (610) 558-9800**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 28, 2008, the Registrant's wholly owned subsidiary, Endo Pharmaceuticals Inc. ( Endo ) entered into an amendment (the Amendment ) to its license and supply agreement (the Agreement ) with and among Novartis AG and Novartis Consumer Health, Inc. relating to Endo's exclusive U.S. marketing rights for the prescription medicine Voltaren® Gel (diclofenac sodium topical gel) 1%.

The Amendment, among other things, clarifies each party's reporting and compliance with all state law requirements regarding price disclosure and reporting as well as related certifications to applicable government authorities and reimbursement for Medicaid rebate claims.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety to the full text of the Amendment, a copy of which will be filed with the exhibits to the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2008.

**Item 9.01. Financial Statements and Exhibits.**

(a) *Financial Statements of Business Acquired.*

Not applicable.

(b) *Pro Forma Financial Information.*

Not applicable.

(c) *Shell Company Transactions*

Not applicable.

(d) *Exhibits.*

Not applicable.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC.  
(Registrant)

By: /s/ CAROLINE B. MANOGUE  
Name: Caroline B. Manogue  
Title: Executive Vice President,

Chief Legal Officer & Secretary

Dated: March 31, 2008